<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView &amp;noscript=1">
Image 8 (AdobeStock_454502194)
New Healthy Volunteers Clinical Trial

Help in the fight against mental health conditions

💡 Help researchers learn more about a potential new psychedelic medicine for the treatment of depression.

💡 If you qualify to take part, you will receive a stipend to account for your time.

Click here or scroll down to learn about this study's inclusion criteria ⬇️

By signing up to Evrima Connect, you consent to Evrima Technologies' Terms of Service and Privacy Policy.

If you take part in this research study, you will:

Be reimbursed and compensated for your participation

Reimbursement of costs, for out-of-pocket expenses, such as travel and parking. You will also receive a stipend to account for your time.

Help advance potential breakthroughs in clinical research.

Your contribution is valuable, and may eventually impact the lives of other people suffering from mental conditions

🏥 Study Guide

Who can take part in this study?

In order to be eligible to participate in the study, you must meet all of the following:

  • Aged 18 - 65 years old 
  • In good general physical and mental health 
  • History of at least one positive experience with a hallucinogenic or psychedelic drug (not including cannabis products), with the most recent experience over 90 days ago.
  • Your BMI is between 18.0 and 30.0

Who is unable to take part in this study?

Unfortunately, if you meet any of the following, this study is not the right fit for you:

  • Anyone who has previously had a negative experience with any type of hallucinogenic or psychedelic drug.
  • Anyone who has a current (or history of a) diagnosed mental disorder.

How long will the study take?

If you agree to take part, and the study is suitable for you, your participation in the study will require 3 separate clinic visits over a period of 6 weeks. This includes:

  • Screening visit (3 hours): to assess your eligibility for the trial (will occur within 28 days of your dose with the experimental drug).
  • 2-night stay at the clinic (36 hours): includes baseline assessments to make sure you are still eligible for the study. If eligible, you will be admitted to the clinical unit, and on the following day, given a single subcutaneous injection of the experimental drug or placebo. You will then be required to stay overnight for monitoring.
  • Follow up visit: You must attend the study centre once more approximately one-week after treatment for a follow-up visit appointment.

What is the purpose of this study?

This study aims to assess the safety and tolerability of potential psychedelic treatment for some psychiatric conditions such as depression including treatment resistant depression and postpartum depression

Symptoms of treatment-resistant depression and postpartum depression can be anywhere from mild to severe and tend to require trying several approaches to identify what helps. 

The study treatment is not approved in Australia and is therefore considered investigational. You will be monitored closely during the study as this treatment has not been tested in humans before.

 

What are psychedelic or hallucinogenic substances?

Hallucinogenic substances are a group of substances (such as LSD) which alter perception, thoughts and feelings. They can cause sensations and images that may seem real but are not.

Psychedelics are a class of hallucinogenic substances that alter perception and mood as well as other cognitive processes. They work by stimulating or suppressing the activity of neurotransmitters in the brain. Psychedelics have not been shown to lead to dependency or addiction.

 

Where is my nearest study site?

  • PARC Clinical Research
    Royal Adelaide Hospital
    Port Road, Adelaide
    South Australia, Australia 5000

What if I have other questions about the study?

We are here for you! Click or tap this button to send an email to our Patient Experience team: